Tracked deals
5
5 tracked deals across 2019-2022.
Operating Company
Healthcare
CellCarta
Montreal, Quebec, Canada
Global provider of precision medicine testing services, offering integrated analytical platforms across immunology (immune monitoring), histopathology, proteomics, genomics, and digital pathology/AI, plus sample management, logistics, and kitting to support clinical trials and translational research.
- Focus Areas
- Precision medicine testing services, Immunology / immune monitoring, Histopathology
- Website
- cellcarta.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Addon
2 addon · 2 buyout · 1 divestiture
CellCarta Acquisition Volume by Year
Last 3 years
Supporting Data
Recent Transactions
-
- Buyer
- CellCarta
- Target
- Precision Assays
- Seller
- Precision Assays
- Industry
- Healthcare Services
- Location
- Washington, United States
- Type
- Divestiture
CellCarta acquired the commercial rights to antibody panels and next‑generation immuno‑MRM assays from Fred Hutch spin‑off Precision Assays, expanding its off‑the‑shelf multiplex proteomics offerings for immuno‑oncology. The deal brings validated CPTAC‑characterized assays into CellCarta's global precision‑medicine service platform, enabling faster deployment in translational and clinical studies.
-
December 14, 2021
- Buyer
- CellCarta
- Target
- Biogazelle
- Industry
- Biotechnology
- Location
- East Flanders, Belgium
- Type
- Buyout
CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.
-
May 11, 2021
- Buyer
- CellCarta
- Target
- Reveal Biosciences
- Industry
- Healthcare Services
- Location
- California, United States
- Type
- Buyout
CellCarta has acquired Reveal Biosciences, a San Diego–based computational pathology company specializing in AI-driven quantitative pathology and digital image analysis. The acquisition adds Reveal's imageDx platform and AI-based pathology capabilities to CellCarta's histological biomarker and precision medicine services, broadening its AI-enabled multi-omic analysis offerings for biopharmaceutical research and clinical trials.
-
January 7, 2021
- Buyer
- Caprion-HistoGeneX, Arsenal Capital Partners
- Target
- Clinical Logistics Inc.
- Industry
- Healthcare Services
- Location
- Nova Scotia, Canada
- Type
- Addon
Caprion-HistoGeneX, a portfolio company backed by Arsenal Capital Partners, has acquired Clinical Logistics Inc. (CLI), a Halifax-based virtual central specimen management CRO. The acquisition expands Caprion-HistoGeneX’s specimen logistics and kitting capabilities to better support global clinical trial operations and specialty specimen handling for pharmaceutical and biotech customers.
-
- Buyer
- Caprion Biosciences, GHO Capital Partners LLP
- Target
- Serametrix Corporation
- Industry
- Healthcare Services
- Location
- California, United States
- Type
- Addon
Caprion Biosciences, a GHO Capital portfolio company, has acquired Serametrix Corporation, a CLIA-certified immune monitoring services provider headquartered in Carlsbad, California. The deal expands Caprion's immunology biomarker capabilities—notably Serametrix's MDSC analysis expertise—and extends Caprion's global footprint with Serametrix's operations in the US, UK, Australia and China.
Related Acquisition Pages
Selling a company? Get in front of buyers like CellCarta
Turn tracked acquisition activity into an outreach-ready buyer list.